Track Caladrius Biosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Caladrius Biosciences, Inc. CLBS · Stock Open Caladrius Biosciences, Inc. in new tab

0.4264 USD
Loading chart...

DCF valuation

Model fair value for Caladrius Biosciences, Inc. (CLBS)
Result
Sign in to run the valuation for CLBS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Caladrius Biosciences, Inc. Logo Caladrius Biosciences, Inc. Analysis (CLBS)

United States Health Care Official Website Stock

Is Caladrius Biosciences, Inc. a good investment? Caladrius Biosciences, Inc. (CLBS) is currently trading at 0.4264 USD.

Investor FAQ

Does Caladrius Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Caladrius Biosciences, Inc.?

Caladrius Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Exchange Ticker
NMS (United States) CLBS
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2013
0.00 USD
Oct. 28, 2013 0.0021
▸2011
0.00 USD
April 4, 2011 0.0002
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion